Dentsply - Weltmarktführer Dentalmaterialien - 500 Beiträge pro Seite
eröffnet am 21.01.10 15:55:44 von
neuester Beitrag 17.02.17 23:35:13 von
neuester Beitrag 17.02.17 23:35:13 von
Beiträge: 20
ID: 1.155.464
ID: 1.155.464
Aufrufe heute: 0
Gesamt: 2.092
Gesamt: 2.092
Aktive User: 0
ISIN: US24906P1093 · WKN: A2AF0E · Symbol: DY2
28,89
EUR
+0,17 %
+0,05 EUR
Letzter Kurs 24.04.24 Tradegate
Neuigkeiten
09.04.24 · globenewswire  |
29.02.24 · globenewswire |
29.02.24 · globenewswire |
29.01.24 · globenewswire |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 142,48 | +94,46 | |
| 2,8800 | +51,58 | |
| 0,5340 | +26,09 | |
| 0,5740 | +13,44 | |
| 2,2800 | +11,76 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,4240 | -12,37 | |
| 0,5340 | -13,87 | |
| 0,5925 | -15,36 | |
| 4,1575 | -21,11 | |
| 2,1500 | -36,79 |
Feedback
DENTSPLY Overview: Manufacturer of Dental Products
For over a century, DENTSPLY International has been committed to providing the dental community with innovative, high quality, cost effective dental products. From our humble beginnings in 1899, the Company has grown to become the largest professional dental products company in the world. From our facilities in 38 nations on six continents, the Company distributes its dental products in over 120 countries under some of the most well established brand names in the dental industry. Worldwide, the profession now depends upon DENTSPLY for innovative new products that advance the practice of dentistry.
For over a century, DENTSPLY International has been committed to providing the dental community with innovative, high quality, cost effective dental products. From our humble beginnings in 1899, the Company has grown to become the largest professional dental products company in the world. From our facilities in 38 nations on six continents, the Company distributes its dental products in over 120 countries under some of the most well established brand names in the dental industry. Worldwide, the profession now depends upon DENTSPLY for innovative new products that advance the practice of dentistry.
!
Dieser Beitrag wurde moderiert. Grund: Provokation
Antwort auf Beitrag Nr.: 38.783.007 von EPB am 21.01.10 16:05:53Was hast Du für ein Problem?
Ist ein grundsolider Wert mit kontunierlichem Wachstum und guter EK-Rendite.
Ist ein grundsolider Wert mit kontunierlichem Wachstum und guter EK-Rendite.
Antwort auf Beitrag Nr.: 38.783.043 von R-BgO am 21.01.10 16:08:47Kann ich nur bestätigen 
,arbeite für Degudent und wir gehören zu Dentsply 
,haben ganz gut zu tun und letztes jahr keine Kurzarbeit und bis jetzt sieht es auch ganz gut aus ,ist halt keine 1000% aktie aber dafür solide
,arbeite für Degudent und wir gehören zu Dentsply 
,haben ganz gut zu tun und letztes jahr keine Kurzarbeit und bis jetzt sieht es auch ganz gut aus ,ist halt keine 1000% aktie aber dafür solide
DENTSPLY INTERNATIONAL INC.
REPORTS FOURTH QUARTER AND FULL YEAR RESULTS
- Fourth quarter net sales increased 11.9% or 11.3%, excluding precious metal content
- Non-GAAP earnings per share increased 6.7% to $0.48, a record for the fourth quarter
- Full year operating cash flow increased 7.9% to $362 million
York, PA – February 10, 2010 – DENTSPLY International Inc. (NASDAQ–XRAY) today announced sales
and earnings for the three months and year ended December 31, 2009.
Fourth Quarter Results
Net sales in the fourth quarter of 2009 increased 11.9% to $568.7 million, compared to $508.1 million
reported in the fourth quarter of 2008. Net sales, excluding precious metal content, increased 11.3% in the
fourth quarter of 2009 over the same period in 2008. Net sales, excluding precious metal content, were
favorably impacted by positive internal growth, acquisitions and the benefit of a weakening U.S. dollar during
the quarter when compared to the same period last year. Net sales, excluding precious metal content, of
dental consumable products and dental specialty products experienced positive internal growth in the period.
Net income attributable to DENTSPLY International for the fourth quarter of 2009 was $74.8 million, or $0.50
per diluted share, compared to $71.0 million, or $0.47 per diluted share, in the fourth quarter of 2008. Net
income attributable to DENTSPLY International in the fourth quarter of each of 2009 and 2008 included
positive tax adjustments and charges for restructuring, impairments and other related items that on a net
basis increased diluted earnings per share by $.02.
Adjusted earnings (excluding tax adjustments, acquisition related activity, and restructuring, impairments and
other related items), which constitute a non-GAAP measure, were $72.6 million, or $0.48 per diluted share, in
the fourth quarter of 2009. This compares to $67.8 million, or $0.45 per diluted share, in the fourth quarter of
2008, or an increase in earnings per diluted share of 6.7% for the quarter. A reconciliation of this non-GAAP
measure to earnings per share on a GAAP basis is provided in the attached table.
REPORTS FOURTH QUARTER AND FULL YEAR RESULTS
- Fourth quarter net sales increased 11.9% or 11.3%, excluding precious metal content
- Non-GAAP earnings per share increased 6.7% to $0.48, a record for the fourth quarter
- Full year operating cash flow increased 7.9% to $362 million
York, PA – February 10, 2010 – DENTSPLY International Inc. (NASDAQ–XRAY) today announced sales
and earnings for the three months and year ended December 31, 2009.
Fourth Quarter Results
Net sales in the fourth quarter of 2009 increased 11.9% to $568.7 million, compared to $508.1 million
reported in the fourth quarter of 2008. Net sales, excluding precious metal content, increased 11.3% in the
fourth quarter of 2009 over the same period in 2008. Net sales, excluding precious metal content, were
favorably impacted by positive internal growth, acquisitions and the benefit of a weakening U.S. dollar during
the quarter when compared to the same period last year. Net sales, excluding precious metal content, of
dental consumable products and dental specialty products experienced positive internal growth in the period.
Net income attributable to DENTSPLY International for the fourth quarter of 2009 was $74.8 million, or $0.50
per diluted share, compared to $71.0 million, or $0.47 per diluted share, in the fourth quarter of 2008. Net
income attributable to DENTSPLY International in the fourth quarter of each of 2009 and 2008 included
positive tax adjustments and charges for restructuring, impairments and other related items that on a net
basis increased diluted earnings per share by $.02.
Adjusted earnings (excluding tax adjustments, acquisition related activity, and restructuring, impairments and
other related items), which constitute a non-GAAP measure, were $72.6 million, or $0.48 per diluted share, in
the fourth quarter of 2009. This compares to $67.8 million, or $0.45 per diluted share, in the fourth quarter of
2008, or an increase in earnings per diluted share of 6.7% for the quarter. A reconciliation of this non-GAAP
measure to earnings per share on a GAAP basis is provided in the attached table.
Trading Spotlight
On Thursday July 29, 2010, 11:55 am EDT
YORK, Pa. (AP) -- Dental products maker Dentsply International Inc. said Thursday its second-quarter profit rose 3 percent as an improved global economy boosted its sales.
Dentsply said it earned $72.4 million, or 49 cents per share, over the three months that ended June 30. That's up from $70.2 million, or 47 cents per share, a year earlier.
Excluding one-time costs and gains, it reported a profit of 50 cents per share. Its revenue grew 2 percent, to $565.1 million from $552.8 million.
Analysts on average were expecting a profit of 50 cents per share and $570.8 million in revenue, according to Thomson Reuters.
CEO Bret Wise said the company's results have slowly improved over the first six months of the year.
"The dental markets have shown a modest recovery in the first half of 2010," he said in a press release. However the company cut its profit expectations for the full year, pointing to the stronger dollar, which hurts its sales overseas.
Dentsply now expects a profit of $1.86 to $1.94 per share for the year, down from $1.90 to $2 per share. Analysts expect $1.93 per share on average.
In morning trading, Dentsply stock fell 81 cents, or 2.8 percent, to $28.65.
YORK, Pa. (AP) -- Dental products maker Dentsply International Inc. said Thursday its second-quarter profit rose 3 percent as an improved global economy boosted its sales.
Dentsply said it earned $72.4 million, or 49 cents per share, over the three months that ended June 30. That's up from $70.2 million, or 47 cents per share, a year earlier.
Excluding one-time costs and gains, it reported a profit of 50 cents per share. Its revenue grew 2 percent, to $565.1 million from $552.8 million.
Analysts on average were expecting a profit of 50 cents per share and $570.8 million in revenue, according to Thomson Reuters.
CEO Bret Wise said the company's results have slowly improved over the first six months of the year.
"The dental markets have shown a modest recovery in the first half of 2010," he said in a press release. However the company cut its profit expectations for the full year, pointing to the stronger dollar, which hurts its sales overseas.
Dentsply now expects a profit of $1.86 to $1.94 per share for the year, down from $1.90 to $2 per share. Analysts expect $1.93 per share on average.
In morning trading, Dentsply stock fell 81 cents, or 2.8 percent, to $28.65.
Na ist hier noch wer Investiert ? und gibt es mal wieder was neues von Dentsply ?
Antwort auf Beitrag Nr.: 40.620.763 von MANRoland am 01.12.10 09:10:41Sie troddeln so langsam vor sich hin; angenehm langweilig:
York, PA – October 28, 2010 -- DENTSPLY International Inc. (NASDAQ–XRAY) today announced sales and earnings for the three months ended September 30, 2010. Net sales in the third quarter of 2010 increased 2.0% to $541.8 million compared to $531.2 million reported for the third quarter of 2009. Net sales, excluding precious metal content, increased 0.1%, including 2.4% growth on a constant currency basis, to $494.3 million in the third quarter of 2010. This constant currency growth was nearly offset by the negative impact of foreign currency translation in the period.
Net income attributable to DENTSPLY International for the third quarter of 2010 was $63.7 million, or $0.44 per diluted share, compared to $0.45 per diluted share in the third quarter of 2009. Net income attributable to DENTSPLY International in the third quarter of 2010 included the net of tax impact of restructuring and other costs of $0.2 million, a net of tax impact for recent acquisition-related activities of $1.3 million and a net benefit for income tax-related adjustments of $0.3 million, which in aggregate reduced earnings per share on a net basis by $.01 per diluted share. Net income attributable to DENTSPLY International in the third quarter of 2009 included the net of tax impact of restructuring and other costs of $0.8 million, a net of tax impact for recent acquisition-related activities of $0.1 million and a net benefit for income tax-related adjustments of $2.6 million, which in aggregate increased earnings per share on a net basis by $0.01 per diluted share. For a reconciliation of GAAP and non-GAAP measures, see the attached table.
Bret Wise, Chairman and Chief Executive Officer, stated “The global dental market continued to grow modestly in the third quarter, with international markets being more resilient. We have now completed the sales and marketing expansion announced early in the year, with the resources fully in place. We are also continuing to make additional investments in the back half of 2010 to take better advantage of a strong product pipeline targeted for launch in 2011 and 2012. Based on these investments and current exchange rates, we are narrowing our 2010 earnings guidance to $1.86 to $1.91 per diluted share.” This guidance for earnings per diluted share is on a non-GAAP basis, excluding restructuring and other costs, acquisition-related activities, a credit risk adjustment to outstanding derivatives and income tax-related adjustments.
York, PA – October 28, 2010 -- DENTSPLY International Inc. (NASDAQ–XRAY) today announced sales and earnings for the three months ended September 30, 2010. Net sales in the third quarter of 2010 increased 2.0% to $541.8 million compared to $531.2 million reported for the third quarter of 2009. Net sales, excluding precious metal content, increased 0.1%, including 2.4% growth on a constant currency basis, to $494.3 million in the third quarter of 2010. This constant currency growth was nearly offset by the negative impact of foreign currency translation in the period.
Net income attributable to DENTSPLY International for the third quarter of 2010 was $63.7 million, or $0.44 per diluted share, compared to $0.45 per diluted share in the third quarter of 2009. Net income attributable to DENTSPLY International in the third quarter of 2010 included the net of tax impact of restructuring and other costs of $0.2 million, a net of tax impact for recent acquisition-related activities of $1.3 million and a net benefit for income tax-related adjustments of $0.3 million, which in aggregate reduced earnings per share on a net basis by $.01 per diluted share. Net income attributable to DENTSPLY International in the third quarter of 2009 included the net of tax impact of restructuring and other costs of $0.8 million, a net of tax impact for recent acquisition-related activities of $0.1 million and a net benefit for income tax-related adjustments of $2.6 million, which in aggregate increased earnings per share on a net basis by $0.01 per diluted share. For a reconciliation of GAAP and non-GAAP measures, see the attached table.
Bret Wise, Chairman and Chief Executive Officer, stated “The global dental market continued to grow modestly in the third quarter, with international markets being more resilient. We have now completed the sales and marketing expansion announced early in the year, with the resources fully in place. We are also continuing to make additional investments in the back half of 2010 to take better advantage of a strong product pipeline targeted for launch in 2011 and 2012. Based on these investments and current exchange rates, we are narrowing our 2010 earnings guidance to $1.86 to $1.91 per diluted share.” This guidance for earnings per diluted share is on a non-GAAP basis, excluding restructuring and other costs, acquisition-related activities, a credit risk adjustment to outstanding derivatives and income tax-related adjustments.
DENTSPLY Ties Up with Korean Firm
December 10, 2010 | Comments: 0
Leading dental products maker DENTSPLY International (XRAY - Analyst Report) has collaborated with South-Korean dental implant devices maker DIO Corporation. The companies will focus on dental implant production across Asia and Europe leveraging their top-notch manufacturing capabilities.
Busan-based DIO Corporation produces a broad range of dental implants (including BioTite-H and SM implant), dental devices and associated accessories. It is an established player in the South Korean dental implant market with presence across several emerging markets, which bode well for DENTSPLY’s international expansion strategy.
Under the agreement,DENTSPLY will initially retain less than 20% of DIO and will make an additional investment in debentures with an option to convert into shares after a year. The deal offers opportunities for synergies and is expected to be modestly accretive to DENTSPLY’s adjusted (excluding transaction costs) earnings in the first year following the transaction closure, which is expected imminently.
DENTSPLY has a strong international presence. The company’s products are used in over 120 countries enabling it to leverage the changing dental practice across North America and Western Europe, which emphasizes preventive care and cosmetic dentistry. One of the company’s major customers is Henry Schein Inc (HSIC - Snapshot Report), a dental products distributor.
DENTSPLY is pursuing an aggressive acquisition strategy to boost growth. The company is devoting a major portion of its cash flows to acquisitions and share repurchases.
Moving forward, DENTSPLY is expected to benefit from the recovery in the global dental market with several product segments and geographies showing signs of growth. Not being a life-sustaining product, the dental market was badly affected by the economic downturn that resulted in patients deferring their adoption.
DENTSPLY's diverse product range, significant international presence, new product introductions and acquisition initiatives are expected to boost operating metrics over the forthcoming quarters. Moreover, the company is poised to grow its share of the dental implant market driven by a strong product base and significant investment on product/technology innovation and sales/marketing infrastructure.
However, DENTSPLY’s international operations are exposed to foreign exchange translation risk given the devaluation of the euro against the U.S. dollar. Moreover, growth in the company’s domestic market has ebbed due to a slow economic recovery and competitive pressure. We are currently Neutral on DENTSPLY.
December 10, 2010 | Comments: 0
Leading dental products maker DENTSPLY International (XRAY - Analyst Report) has collaborated with South-Korean dental implant devices maker DIO Corporation. The companies will focus on dental implant production across Asia and Europe leveraging their top-notch manufacturing capabilities.
Busan-based DIO Corporation produces a broad range of dental implants (including BioTite-H and SM implant), dental devices and associated accessories. It is an established player in the South Korean dental implant market with presence across several emerging markets, which bode well for DENTSPLY’s international expansion strategy.
Under the agreement,DENTSPLY will initially retain less than 20% of DIO and will make an additional investment in debentures with an option to convert into shares after a year. The deal offers opportunities for synergies and is expected to be modestly accretive to DENTSPLY’s adjusted (excluding transaction costs) earnings in the first year following the transaction closure, which is expected imminently.
DENTSPLY has a strong international presence. The company’s products are used in over 120 countries enabling it to leverage the changing dental practice across North America and Western Europe, which emphasizes preventive care and cosmetic dentistry. One of the company’s major customers is Henry Schein Inc (HSIC - Snapshot Report), a dental products distributor.
DENTSPLY is pursuing an aggressive acquisition strategy to boost growth. The company is devoting a major portion of its cash flows to acquisitions and share repurchases.
Moving forward, DENTSPLY is expected to benefit from the recovery in the global dental market with several product segments and geographies showing signs of growth. Not being a life-sustaining product, the dental market was badly affected by the economic downturn that resulted in patients deferring their adoption.
DENTSPLY's diverse product range, significant international presence, new product introductions and acquisition initiatives are expected to boost operating metrics over the forthcoming quarters. Moreover, the company is poised to grow its share of the dental implant market driven by a strong product base and significant investment on product/technology innovation and sales/marketing infrastructure.
However, DENTSPLY’s international operations are exposed to foreign exchange translation risk given the devaluation of the euro against the U.S. dollar. Moreover, growth in the company’s domestic market has ebbed due to a slow economic recovery and competitive pressure. We are currently Neutral on DENTSPLY.
Hzl-Msj, On Friday January 7, 2011, 12:48 pm EST
NEW YORK (AP) -- Dentsply International Inc. said Friday it is partnering with GlaxoSmithKline PLC to make new treatments for sensitive teeth.
GlaxoSmithKline sells Sensodyne brand toothpaste, and Dentsply sells Nupro products, which are prophy pastes -- abrasive toothpastes dentists and dental hygienists use to take buildup off patients' teeth. Dentsply said the co-branded products will be used in dentists' offices. It will start by selling Nupro Sensodyne prophy paste and Sensodyne Nupro, a toothpaste for dentists to give out at their offices.
The agreement does not involve cash or equity from either company.
Nupro products use technology developed by a company called NovaMin. GlaxoSmithKline bought NovaMin in December 2009.
Dentsply is based in York, Pa., and its shares gave up 31 cents to $34.52 in afternoon trading. Shares of GlaxoSmithKline, which is based in London, fell 29 cents to $38.76 in U.S. trading.
NEW YORK (AP) -- Dentsply International Inc. said Friday it is partnering with GlaxoSmithKline PLC to make new treatments for sensitive teeth.
GlaxoSmithKline sells Sensodyne brand toothpaste, and Dentsply sells Nupro products, which are prophy pastes -- abrasive toothpastes dentists and dental hygienists use to take buildup off patients' teeth. Dentsply said the co-branded products will be used in dentists' offices. It will start by selling Nupro Sensodyne prophy paste and Sensodyne Nupro, a toothpaste for dentists to give out at their offices.
The agreement does not involve cash or equity from either company.
Nupro products use technology developed by a company called NovaMin. GlaxoSmithKline bought NovaMin in December 2009.
Dentsply is based in York, Pa., and its shares gave up 31 cents to $34.52 in afternoon trading. Shares of GlaxoSmithKline, which is based in London, fell 29 cents to $38.76 in U.S. trading.
Dividende wurde um 10% auf 5,5c erhöht
Nachdem die Übernahme von ASTRA Tech bestätigt ist dürfte Aktie sich weiter festigen und die 30 er marke knacken .
Antwort auf Beitrag Nr.: 42.637.548 von MANRoland am 24.01.12 10:12:34gute Prognose!
Obwohl mir persönlich die Q1-Zahlen eher nicht so gut gefielen...
Obwohl mir persönlich die Q1-Zahlen eher nicht so gut gefielen...
dehistorize
Antwort auf Beitrag Nr.: 46.592.445 von R-BgO am 09.03.14 11:09:50http://investor.dentsply.com/phoenix.zhtml?c=76841&p=quarter…
http://de.4-traders.com/DENTSPLY-INTERNATIONAL-IN-4916/funda…
http://de.4-traders.com/DENTSPLY-INTERNATIONAL-IN-4916/funda…
sie übernehmen Sirona: http://www.handelsblatt.com/unternehmen/industrie/sirona-geh…
Antwort auf Beitrag Nr.: 50.643.447 von R-BgO am 17.09.15 10:39:50
http://seekingalpha.com/news/3148906-dentsply-sirona-complet…
The previously announced merger between Dentsply (XRAY +0.6%) and Sirona Dental Systems (SIRO) has been completed. Under the terms of the all-stock transaction, Sirona shareholders received 1.8142 shares of XRAY for each Sirona share. SIRO will cease trading today." target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/news/3148906-dentsply-sirona-complet…
The previously announced merger between Dentsply (XRAY +0.6%) and Sirona Dental Systems (SIRO) has been completed. Under the terms of the all-stock transaction, Sirona shareholders received 1.8142 shares of XRAY for each Sirona share. SIRO will cease trading today.
Zitat von R-BgO: sie übernehmen Sirona: http://www.handelsblatt.com/unternehmen/industrie/sirona-geh…
http://seekingalpha.com/news/3148906-dentsply-sirona-complet…
The previously announced merger between Dentsply (XRAY +0.6%) and Sirona Dental Systems (SIRO) has been completed. Under the terms of the all-stock transaction, Sirona shareholders received 1.8142 shares of XRAY for each Sirona share. SIRO will cease trading today." target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/news/3148906-dentsply-sirona-complet…
The previously announced merger between Dentsply (XRAY +0.6%) and Sirona Dental Systems (SIRO) has been completed. Under the terms of the all-stock transaction, Sirona shareholders received 1.8142 shares of XRAY for each Sirona share. SIRO will cease trading today.
June 27, 2016
DENTSPLY SIRONA ANNOUNCES ACQUISITION OF MIS IMPLANTS
York, Pennsylvania, June 27, 2016 - DENTSPLY SIRONA Inc. ("Dentsply Sirona") (NASDAQ: XRAY), The Dental Solutions Company, today announced a definitive agreement to acquire all of the outstanding shares of privately held MIS Implants Technologies Ltd. ("MIS"), a dental implant systems manufacturer headquartered in northern Israel, for $375 million in cash.
MIS is a growing and profitable manufacturer of dental implant systems with annual sales of approximately $80 million. The company is a leader in the value segment of the market, selling its products under the MIS brand through a wide distribution network that includes a direct sales force, reaching over 65 countries.
Jeffery T. Slovin, Chief Executive Officer of Dentsply Sirona, commented, "MIS is uniquely positioned to address the value segment of the market in both its home region and around the globe. It is strategically important to be able to address the entire multi-billion dollar implant market with distinct organizations, portfolios and brands targeting both the premium and value segments. MIS has a broad portfolio of implants and related products under a well-established brand making it a great complement to our company. This acquisition underscores our commitment to deploying capital to drive growth and create shareholder value."
Dentsply Sirona expects this transaction to be accretive to adjusted earnings per share within the first twelve months following the closing of the transaction. Moelis & Company acted as financial advisor to Dentsply Sirona.
DENTSPLY SIRONA ANNOUNCES ACQUISITION OF MIS IMPLANTS
York, Pennsylvania, June 27, 2016 - DENTSPLY SIRONA Inc. ("Dentsply Sirona") (NASDAQ: XRAY), The Dental Solutions Company, today announced a definitive agreement to acquire all of the outstanding shares of privately held MIS Implants Technologies Ltd. ("MIS"), a dental implant systems manufacturer headquartered in northern Israel, for $375 million in cash.
MIS is a growing and profitable manufacturer of dental implant systems with annual sales of approximately $80 million. The company is a leader in the value segment of the market, selling its products under the MIS brand through a wide distribution network that includes a direct sales force, reaching over 65 countries.
Jeffery T. Slovin, Chief Executive Officer of Dentsply Sirona, commented, "MIS is uniquely positioned to address the value segment of the market in both its home region and around the globe. It is strategically important to be able to address the entire multi-billion dollar implant market with distinct organizations, portfolios and brands targeting both the premium and value segments. MIS has a broad portfolio of implants and related products under a well-established brand making it a great complement to our company. This acquisition underscores our commitment to deploying capital to drive growth and create shareholder value."
Dentsply Sirona expects this transaction to be accretive to adjusted earnings per share within the first twelve months following the closing of the transaction. Moelis & Company acted as financial advisor to Dentsply Sirona.
Antwort auf Beitrag Nr.: 50.643.447 von R-BgO am 17.09.15 10:39:50
zieht natürlich die Eigenkapitalquote hoch und die EK-Rendite runter.
Ansonsten scheinen sie weiter wie blöde Aktien zurückzukaufen.
die Bilanz sieht schon drastisch anders aus jetzt:
ungefähr 6,5 Mrd. $ zusätzliche Intangibles...zieht natürlich die Eigenkapitalquote hoch und die EK-Rendite runter.
Ansonsten scheinen sie weiter wie blöde Aktien zurückzukaufen.
Antwort auf Beitrag Nr.: 52.832.839 von R-BgO am 14.07.16 14:05:12hier geht's weiter Thread: Dentsply Sirona
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -2,56 | |
| -0,37 | |
| +0,04 | |
| +0,24 | |
| -0,73 | |
| -3,16 | |
| +0,33 | |
| -0,21 | |
| -0,05 | |
| -0,47 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 224 | ||
| 136 | ||
| 117 | ||
| 76 | ||
| 43 | ||
| 37 | ||
| 37 | ||
| 34 | ||
| 31 | ||
| 30 |
| Zeit | Titel |
|---|---|
| 15.04.24 |